These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2996688)

  • 1. Persistence of antibrain antibodies in cerebrospinal fluid during plasmapheresis for multiple sclerosis.
    Ryberg B; Pirskanen R
    Br Med J (Clin Res Ed); 1985 Sep; 291(6499):850-1. PubMed ID: 2996688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A longitudinal study of antibrain antibodies in multiple sclerosis.
    Ryberg B
    J Neurol Sci; 1982 May; 54(2):263-70. PubMed ID: 6284884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal and extrathecal production of antibrain antibodies in multiple sclerosis.
    Ryberg B
    J Neurol Sci; 1980 Oct; 48(1):1-8. PubMed ID: 7420122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmapheresis in multiple sclerosis: preliminary study.
    Weiner HL; Dawson DM
    Neurology; 1980 Oct; 30(10):1029-33. PubMed ID: 7191492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmapheresis in multiple sclerosis: preliminary findings.
    Dau PC; Petajan JH; Johnson KP; Panitch HS; Bornstein MB
    Neurology; 1980 Oct; 30(10):1023-8. PubMed ID: 6448360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement-fixing antibrain antibodies in multiple sclerosis. Comparison of their occurrence in cerebrospinal fluid and serum.
    Ryberg B
    Acta Neurol Scand; 1976 Jul; 54(1):1-12. PubMed ID: 936972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin characterization by bacterial absorption of antibrain antibodies in multiple sclerosis.
    Ryberg B; Kronvall G
    Eur Neurol; 1981; 20(5):374-9. PubMed ID: 7285987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple specificities of antibrain antibodies in multiple sclerosis and chronic myelopathy.
    Ryberg B
    J Neurol Sci; 1978 Oct; 38(3):357-82. PubMed ID: 731263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Virus neutralizing and antibrain antibodies in multiple sclerosis and multiple encephalomyelitis].
    Zinchenko AP; Shamreĭ RK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1968; 68(4):541-8. PubMed ID: 4301248
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current therapy of multiple sclerosis. Are there indications for plasmapheresis?].
    Schönbeck S; Hohlfeld R
    Nervenarzt; 1992 Feb; 63(2):116-9. PubMed ID: 1314334
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders.
    Reindl M; Khantane S; Ehling R; Schanda K; Lutterotti A; Brinkhoff C; Oertle T; Schwab ME; Deisenhammer F; Berger T; Bandtlow CE
    J Neuroimmunol; 2003 Dec; 145(1-2):139-47. PubMed ID: 14644040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of ACTH therapy on IgG synthesis in cerebrospinal fluid spaces in patients with disseminated sclerosis].
    Wender M; Michałowska G; Wajgt A
    Neurol Neurochir Pol; 1986; 20(5):437-43. PubMed ID: 3035406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating efficacy of plasmapheresis for patients with pemphigus using desmoglein enzyme-linked immunosorbent assay.
    Nagasaka T; Fujii Y; Ishida A; Handa M; Tanikawa A; Amagai M; Nishikawa T
    Br J Dermatol; 2008 Apr; 158(4):685-90. PubMed ID: 18241273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases.
    Rawes JA; Calabrese VP; Khan OA; DeVries GH
    Mult Scler; 1997 Dec; 3(6):363-9. PubMed ID: 9493635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antibodies against encephalitogenic protein and myelin glycoprotein in the cerebrospinal fluid of patients with multiple sclerosis. Effect of encorton treatment on the autoantibody and immune complex levels].
    Waigt A; Górny MK
    Folia Med Cracov; 1984; 25(3-4):307-18. PubMed ID: 6085729
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasmapheresis, lymphocytapheresis, and immunosuppressive drug therapy in multiple sclerosis.
    Hauser SL; Fosburg M; Kevy S; Weiner HL
    Prog Clin Biol Res; 1982; 106():239-54. PubMed ID: 6184727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement-fixing antibrain antibodies in multiple sclerosis. A preliminary report.
    Laurell AB; Link H
    Acta Neurol Scand; 1972; 48(4):461-6. PubMed ID: 5072655
    [No Abstract]   [Full Text] [Related]  

  • 18. Different types of antibrain antibodies in multiple sclerosis. Studies employing myelin-deficient mutants of mice.
    Ryberg B; Baumann NA
    J Neurol Sci; 1983 Mar; 58(3):351-5. PubMed ID: 6842263
    [No Abstract]   [Full Text] [Related]  

  • 19. Antibrain antibodies in multiple sclerosis. Relation to clinical variables.
    Ryberg B
    J Neurol Sci; 1982 May; 54(2):239-61. PubMed ID: 7097299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ontogenetic mouse brain model employed in the characterization of antibrain antibodies in multiple sclerosis.
    Ryberg B
    J Neuroimmunol; 1983 Feb; 4(1):9-15. PubMed ID: 6185539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.